Staccato Alprazolam and Photoparoxysmal Response
| 대상 질환 | Epilepsy |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Nova Pneuma Inc. |
| 상태 | 완료 |
| 참여자 수 | 5 명 |
| 중재(약물) | A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 m, D= Inhaled Alprazolam 2 mg, E=Placebo |
| 시작일 | 2015년 1월 |
| 완료일 | 2016년 7월 |
| 결과 공개일 | 2021년 8월 10일 |
요약
The purpose of this study is to determine whether people who usually have photosensitive epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato Alprazolam as compared to placebo.
Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR)
| Inhaled Placebo | -0.2 Number of frequency steps |
|---|---|
| Staccato Alprazolam, 0.5 mg | -4.4 Number of frequency steps |
| Staccato Alprazolam, 1 mg | -5.2 Number of frequency steps |
| Staccato Alprazolam, 2 mg | -4.8 Number of frequency steps |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner